Published in Acta Oncol on January 01, 1994
The National Awareness and Early Diagnosis Initiative in England: assembling the evidence. Br J Cancer (2009) 3.80
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer (1999) 2.89
Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ (2000) 2.80
Who and what influences delayed presentation in breast cancer? Br J Cancer (1998) 2.53
Patient delay and stage of diagnosis among breast cancer patients in Germany -- a population based study. Br J Cancer (2002) 2.34
Waiting time for breast cancer surgery in Quebec. CMAJ (2001) 2.29
Socioeconomic patient characteristics predict delay in cancer diagnosis: a Danish cohort study. BMC Health Serv Res (2008) 2.28
Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients. BMC Health Serv Res (2011) 2.23
Knowledge, attitude and practice of Nigerian women towards breast cancer: a cross-sectional study. World J Surg Oncol (2006) 2.09
Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol (2012) 1.49
Delay in diagnosis of breast cancer. Ann Surg (1999) 1.33
Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. Cancer Epidemiol Biomarkers Prev (2008) 1.23
Patient and provider delays in breast cancer patients attending a tertiary care centre: a prospective study. JRSM Short Rep (2011) 1.16
Waiting times for radiotherapy: variation over time and between cancer networks in southeast England. Br J Cancer (2005) 1.11
Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health (2014) 1.06
Mammography screening in the Netherlands: delay in the diagnosis of breast cancer after breast cancer screening. Br J Cancer (2004) 1.03
General practitioner characteristics and delay in cancer diagnosis. a population-based cohort study. BMC Fam Pract (2011) 1.03
What influences diagnostic delay in low-income women with breast cancer? J Womens Health (Larchmt) (2011) 1.00
Process of care failures in breast cancer diagnosis. J Gen Intern Med (2009) 0.92
Radiotherapy waiting times for women with breast cancer: a population-based cohort study. BMC Cancer (2007) 0.89
Intra-urban differences in breast cancer mortality: a study from the city of Malmö in Sweden. J Epidemiol Community Health (2000) 0.80
Patient-expressed perceptions of wait-time causes and wait-related satisfaction. Curr Oncol (2015) 0.78
The Impact of Rurality and Disadvantage on the Diagnostic Interval for Breast Cancer in a Large Population-Based Study of 3202 Women in Queensland, Australia. Int J Environ Res Public Health (2016) 0.75
The Effects of Hospital Characteristics on Delays in Breast Cancer Diagnosis in Appalachian Communities: A Population-Based Study. J Rural Health (2017) 0.75
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med (1997) 10.83
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet (1999) 8.44
Genetic Control of Flower Development by Homeotic Genes in Antirrhinum majus. Science (1990) 7.30
Public-health impact of outdoor and traffic-related air pollution: a European assessment. Lancet (2000) 6.95
Complementary floral homeotic phenotypes result from opposite orientations of a transposon at the plena locus of Antirrhinum. Cell (1993) 4.47
Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology (1992) 4.19
European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology (1984) 4.09
GLOBOSA: a homeotic gene which interacts with DEFICIENS in the control of Antirrhinum floral organogenesis. EMBO J (1992) 3.61
Bracteomania, an inflorescence anomaly, is caused by the loss of function of the MADS-box gene squamosa in Antirrhinum majus. EMBO J (1992) 3.60
Genetic engineering of parthenocarpic plants. Nat Biotechnol (1997) 3.31
The 17-kb Tam1 element of Antirrhinum majus induces a 3-bp duplication upon integration into the chalcone synthase gene. EMBO J (1984) 3.07
Nucleotide sequence of the transposable DNA-element IS2. Nucleic Acids Res (1979) 2.89
Ternary complex formation between the MADS-box proteins SQUAMOSA, DEFICIENS and GLOBOSA is involved in the control of floral architecture in Antirrhinum majus. EMBO J (1999) 2.88
Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ (2000) 2.80
Molecular analysis of instability in flower pigmentation of Antirrhinum majus, following isolation of the pallida locus by transposon tagging. EMBO J (1985) 2.48
Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology (1991) 2.42
Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry (1974) 2.42
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
[Improved prognosis of breast cancer]. Ugeskr Laeger (1994) 2.21
Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am (1997) 2.09
Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol (2000) 1.99
Multiple interactions amongst floral homeotic MADS box proteins. EMBO J (1996) 1.96
Mussel Poisoning. Cal West Med (1935) 1.94
Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr (1992) 1.93
[Surgical treatment of benign recurrent goiter. Technique, complications and permanent sequelae]. Ugeskr Laeger (1994) 1.92
Genetic studies of the lac repressor. IX. Generation of altered proteins by the suppression of nonsence mutations. J Mol Biol (1979) 1.88
PLENA and FARINELLI: redundancy and regulatory interactions between two Antirrhinum MADS-box factors controlling flower development. EMBO J (1999) 1.87
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
The transposable element Tam1 from Antirrhinum majus shows structural homology to the maize transposon En/Spm and has no sequence specificity of insertion. Mol Gen Genet (1991) 1.77
The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat (1994) 1.69
IS1-mediated DNA rearrangements. Cold Spring Harb Symp Quant Biol (1981) 1.68
Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol (1988) 1.65
Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg (1985) 1.65
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol (1987) 1.59
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol (1987) 1.53
Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res (1987) 1.53
Integration of IS3 into IS2 generates a short sequence duplication. Mol Gen Genet (1979) 1.49
Diseases of the urachus simulating intra-abdominal disorders. Am J Surg (1971) 1.47
Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ (2000) 1.47
Segmental portal hypertension. Ann Surg (1986) 1.47
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
[Paraffin embedding for hemispherial slides within 10 days]. Acta Neuropathol (1967) 1.39
Evaluation of routine upper digestive tract endoscopy before laparoscopic cholecystectomy. Br J Surg (1992) 1.38
[Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen]. Ugeskr Laeger (1996) 1.38
[Surgical treatment of primary hyperparathyroidism]. Ugeskr Laeger (1997) 1.38
Strangulated diaphragmatic hernia. A clinical study. Am J Surg (1975) 1.37
[Axillary dissection in primary surgical treatment of breast cancer: risk of false-negative axillary status]. Ugeskr Laeger (1992) 1.37
The importance of surgery and accurate axillary staging for survival in breast cancer. Eur J Surg Oncol (1998) 1.37
Structural analysis of Tam3, a transposable element from Antirrhinum majus, reveals homologies to the Ac element from maize. Plant Mol Biol (1991) 1.36
Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer (1991) 1.36
[St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved]. Fortschr Med (1993) 1.28
Reliability of the 30-minute ACTH test in assessing hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab (1978) 1.27
Should women be advised against pregnancy after breast-cancer treatment? Lancet (1997) 1.26
Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients. Ann Oncol (2003) 1.25
Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol (1988) 1.21
Adenomyoepithelial adenosis and low-grade malignant adenomyoepithelioma of the breast. Virchows Arch A Pathol Anat Histopathol (1984) 1.21
Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood. Clin Exp Immunol (1980) 1.20
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. Eur J Cancer (2007) 1.20
[Mammographic examinations in Denmark, 1990-1991]. Ugeskr Laeger (1994) 1.19
Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer (1992) 1.18
IS2-43 and IS2-44: new alleles of the insertion sequence IS2 which have promoter activity. Mol Gen Genet (1979) 1.18
Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst (1991) 1.18
Organochlorine compounds in human breast fat from deceased with and without breast cancer and in a biopsy material from newly diagnosed patients undergoing breast surgery. Environ Res (1984) 1.17
Molecular characterization of two stamen-specific genes, tap1 and fil1, that are expressed in the wild type, but not in the deficiens mutant of Antirrhinum majus. Mol Gen Genet (1991) 1.17
The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects. Acta Pharmacol Toxicol (Copenh) (1974) 1.15
Quality of life influenced by primary surgical treatment for stage I-III breast cancer-long-term follow-up of a matched-pair analysis. Ann Surg Oncol (2001) 1.15
Cloning of the potato virus Y genes encoding the capsid protein CP and the nuclear inclusion protein NIb. Arch Virol (1989) 1.14
NTGLO: a tobacco homologue of the GLOBOSA floral homeotic gene of Antirrhinum majus: cDNA sequence and expression pattern. Mol Gen Genet (1993) 1.14
Time since childbirth and prognosis in primary breast cancer: population based study. BMJ (1997) 1.13
Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat (2000) 1.12
A new type of IS1-mediated deletion. Mol Gen Genet (1981) 1.11
Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med (1999) 1.10
Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst (1992) 1.10
Anatomic variants of the urachus related to clinical appearance and surgical treatment of urachal lesions. Surg Gynecol Obstet (1973) 1.10
Parity, age at first childbirth and the prognosis of primary breast cancer. Br J Cancer (1998) 1.10
Congenital patient urachus and acquired variants. Diagnosis and treatment. Review of the literature and report of five cases. Acta Chir Scand (1971) 1.08
Axillary dissection in breast cancer. Lancet (1991) 1.07
Dietary fiber and nutrient intake in Crohn's disease. Am J Clin Nutr (1979) 1.07
European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Ann Chir Gynaecol (1998) 1.07
Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol (1994) 1.06
Danish Breast Cancer Cooperative Group (DBCG). Structure and results of the organization. Acta Oncol (1988) 1.05
Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun (1974) 1.05
Primary periareolar abscess in the nonlactating breast: risk of recurrence. Am J Surg (1987) 1.05
Influence of adjuvant irradiation on the development of late arm lymphedema and impaired shoulder mobility after mastectomy for carcinoma of the breast. Acta Oncol (1988) 1.05
Alteration of tobacco floral organ identity by expression of combinations of Antirrhinum MADS-box genes. Plant J (1996) 1.04
Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (1993) 1.03
Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr (1985) 1.03
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. Eur J Cancer Clin Oncol (1984) 1.03